AirSculpt Q2 FY2026 earnings: Stable case volume but weaker margins

AirSculpt Technologies (NASDAQ: AIRS) reported fiscal Q2 2026 revenue of $42.9 million, down 3% from $44.0 million a year earlier, while diluted GAAP loss per share widened to $0.02 from $0.01 for the quarter ended June 30, 2026. Same-center case volume increased 1.0%, but lower revenue per case and higher SG&A expense reduced adjusted EBITDA to $4.9 million and pushed quarterly operating cash flow negative. The company also lowered its full-year adjusted EBITDA outlook.

Core earnings data

The revenue decline reflected a 0.5% decrease in total case volume and an approximately 2.1% reduction in revenue per case. Profitability weakened more quickly than sales: cost of service declined, but SG&A expense increased, resulting in a small operating loss and a lower adjusted EBITDA margin.

The following figures cover the three months ended June 30, 2026.

Adjusted EBITDA and adjusted EBITDA margin are non-GAAP measures. The operating margins above are calculated from the reported revenue and operating income figures.

Business and operating performance

AirSculpt’s same-center metrics were more stable than its consolidated results. Same-center cases increased 1.0%, while same-center revenue per case fell 2.0%; management characterized same-center sales as stable. Total performance also included one fewer facility and two fewer procedure rooms than a year earlier.

The operating data indicate that customer volume at established centers stabilized, but the lower amount of revenue generated per case prevented that improvement from translating into consolidated revenue growth.

Profitability, cash flow and balance sheet

Cost of service declined approximately 3.7% to $16.6 million, broadly tracking the reduction in revenue. SG&A expense, however, increased approximately 3.3% to $23.4 million even as sales fell. Management said AirSculpt stepped up marketing investment during the quarter, though the company did not quantify marketing’s specific contribution to the higher expense.

This cost pattern created negative operating leverage. AirSculpt moved from operating income of $0.8 million to a small operating loss, while adjusted EBITDA margin contracted by 1.8 percentage points. Net loss also widened despite net interest expense declining to $1.0 million from $1.6 million.

Quarterly operating cash flow deteriorated to negative $1.2 million from positive $5.0 million. For the first six months of fiscal 2026, operating cash flow remained positive at $4.0 million, although it was below $5.9 million in the prior-year period.

Cash and cash equivalents reached $18.8 million at June 30, up from $8.4 million at December 31, 2025. During Q2, AirSculpt raised $5.0 million through its at-the-market equity program and repaid $1.4 million of debt. Gross debt stood at approximately $44.2 million, and the company had another $5.0 million of revolving credit capacity.

After quarter-end, AirSculpt amended its term loan to extend maturity to November 2027. It paid $2.5 million when the amendment was signed and must pay another $2.5 million by September 30, 2026. The agreement also requires 50% of net proceeds from most future equity issuances to be applied to term-loan repayment.

Full-year guidance

AirSculpt reaffirmed its fiscal 2026 revenue range but indicated that revenue is now expected near the lower end. It also reduced adjusted EBITDA guidance to approximately $12 million to $14 million, signaling that the company expects the margin pressure seen in the first half to affect the full-year result.

The release did not disclose the previous adjusted EBITDA range, so the size of that reduction cannot be determined from the supplied information.

Management’s view

CEO Yogi Jashnani described Q2 as AirSculpt’s second consecutive quarter of stability. Management’s priorities include increasing brand marketing, introducing additional procedures and broadening the potential patient population.

AirSculpt also entered an exclusive partnership with AlloClae to offer an injectable adipose matrix. Management views the partnership and a broader procedure mix as ways to expand the company’s addressable market, although the release did not provide revenue targets or expected financial contributions from the new offering.

Risks investors should monitor

• Lower revenue per case: Same-center case growth was positive, but a 2.0% decline in same-center revenue per case offset that volume improvement. Continued pressure on per-case economics could limit revenue growth even if demand remains stable.
• Marketing and overhead efficiency: SG&A increased while revenue declined, compressing both GAAP operating margin and adjusted EBITDA margin. Returns from the increased marketing investment will be important to future profitability.
• Cash generation and debt payments: Q2 operating cash flow turned negative, while the amended term loan requires $5.0 million of payments by the end of September, including the amount paid at signing.
• Equity dilution: AirSculpt used its at-the-market program to raise capital, and weighted-average diluted shares increased to 70.8 million from 59.6 million. The amended loan also directs part of the proceeds from most future equity issuances toward debt repayment.
• Smaller operating footprint: The company operated one fewer facility and two fewer procedure rooms than a year earlier, making sustained same-center growth more important to consolidated performance.

Summary

AirSculpt’s fiscal Q2 2026 results showed greater stability in same-center case volume, but that progress did not produce stable earnings. Lower revenue per case and higher SG&A expense compressed margins, widened the GAAP loss and contributed to negative quarterly operating cash flow. Liquidity improved and the debt maturity was extended, although equity financing and additional required repayments remain important considerations. The main issues to monitor are revenue per case, returns on marketing spending, cash conversion and whether results can remain within the revised full-year outlook.